Novocure Limited · NASDAQ:NVCR
Novocure — Investor Presentation (February 2023)
40 slides from Novocure's investor presentation, February 2023
Slide 1: Novocure February 2023
novecure’ Novocure February 2023 patientforward
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding a
Slide 3: Together with our patients, we strive to extend survival
together with our patients, 4 we Strive to extend survival in some of the most aggressive forms of cancer patientforward
Slide 4: Tumor Treating Fields are electric fields that kill cancer cells
novocure’ Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer \ » N TeleEL_L DS cells via a variety of mechanisms “ANA TUMOR TREATING FIELDS THERAPY TTFields spare healthy cells because they have different properties than cancer cells across a range of tumo
Slide 5: Tumor Treating Fields have multiple, distinct mechanisms of action
novecure’ Tumor Treating Fields have multiple, distinct mechanisms of action interference of cell movement and disruption of 4 = . mitosis “ E mechanisms work together to selectively target and disrupt the progression of cancer cells, which can lead os downregulation of . to their death wT downstrea
Slide 6: Optune indicated for adult patients with glioblastoma
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
Slide 7: Glioblastoma: malignant brain cancer
novecure’ glioblastoma: malignant brain cancer WHO grade 4 15,000 cases diagnosed in the U.S. each yeart 49.1% of primary malignant brain tumors? 65: median age of newly diagnosed GBM patient2 14.6 to 16.7 months median overall survival® BeIny (el-sseto) al Stile In) 5-10% five-year survival rate im
Slide 8: Optune: proven to extend patient survival
novecure’ Optune: proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) 0) Siacmento” MSRESma 29 NEARLY HALF eo <0.001 ° of people using = 087 GNESI) _ O.SSI0.550026) 43% Optune + TMZ 3 ord Optune (racian 08 from diagnosis 24
Slide 9: Optune: greater exposure increased survival
novecure’ Optune: greater exposure increased survival MEDIAN OVERALL SURVIVAL BY PERCENT OF TIME ON OPTUNE 25 months P-0.05 22 months P<0.05 Optune + TMZ , = TMZ al 20 months 005 “on OF PATIENTS RECEIVED A SURVIVAL JM te montnsao0s BENEFIT FROM OPTUNE BECAUSE se months THEY USED IT >50% OF THE TIME
Slide 10: Growing body of real-world evidence supporting Optune
novecure’ growing body of real-world evidence supporting Statistically significant improvements in OS CBTRUS Improvements in survival for glioblastoma in the post-Stupp protocol era uv Duke University Suieeghe ee School of Medicine Corey Neff2, Mackenzie Price'?, Gordon Chavez, Christina Proeschold,
Slide 11: A comprehensive strategy for long-term growth
novecure’ a comprehensive strategy for long-term growth drive commercial advance deliver adoption clinical trials product innovation in approved to reach new patient to increase dose and indications populations duration of therapy Built upon a foundation of financial strength and a robust intellectu
Slide 12: Drive commercial adoption
novecure’ drive commercial adoption patientfo rward © 2023Novocure GmbH 12
Slide 13: An established commercial business in GBM
an established commercial business in GBM 10 ACTIVE MARKETS SWEDEN FRANCE.) GERMANY. CANADA, SWITZERLAND: AUSTRIA CHINA UNITED STATES é JAPAN ISRAEL COVERED LIVES GLOBALLY 5,400+ ACTIVE PATIENTS ON THERAPY ANNUAL NET REVENUES patientforward © 2023Novocure GmbH 13
Slide 14: Multiple levers to drive net revenue growth
multiple levers to drive net revenue growth embedded in business model PAYERS ARE BILLED A SINGLE MONTHLY FEE FOR ALL SERVICES AND EQUIPMENT patient INCREASE PENETRATION IN CURRENT MARKETS DEVELOP COMPONENTS TO MAXIMIZE THERAPY AND COMFORT EXPAND INTO NEW MARKETS ENHANCE PATIENT ENGAGEMENT TO INCREA
Slide 15: Comprehensive approach to drive penetration in established markets
comprehensive approach to drive penetration in established markets patientforward STRENGTHEN HCP RECOMMENDATION Educate HCPs on benefits of TTFields therapy INCREASE PATIENT DEMAND Arm patients to advocate for Optune® STREAMLINED ORGANIZATION Creation of U.S. CNS Cancers Franchise intended to renew
Slide 16: Advance clinical trials
novecure’ advance clinical trials patientfo rward © 2023Novocure GmbH 16
Slide 17: Holistic strategy to expand TTFields clinical footprint
holistic strategy to expand TTFields clinical footprint Investigate Expand labels use in new in approved indications L indications Explore additive effects with standards of care
Slide 18: Backbone therapy potential across a range of solid tumors
novecure’ backbone therapy potential with clinical versatility across a range of solid tumors and concurrent therapies IMMUNOTHERAPY Brain — atezolizumab OO ee eae = 3) pembrolizumab L my pon —_ - nivolumab ung Ra, “ ws NS SY ‘ e CHEMOTHERAPY NX ny TTT Ovarian RON aa carboplatin — ’ A . | FIELDS | [
Slide 19: Platform technology driving robust clinical pipeline
novecure’ platform technology driving robust clinical pipeline TRIAL TTFIELDS + | PILOT | PIVOTAL | __ APPROVED EF-14 temozolomide newly diagnosed TRIDENT. temozolomide + radiation CNS glioblastoma temozolomide + : KEYNOTE D58 fanned program pembrolizumab - gliobisstorna EF-L1 monotherapy ED brain m
Slide 20: Late-stage pipeline offers substantial, near-term market expansion opportunity
novecure’ late-stage pipeline offers substantial, near-term market expansion opportunity GLIOBLASTOMA LATE-STAGE PIPELINE 14x CURRENT MARKET OPPORUNITY PANOVA-3 Pancreatic Cancer ~35% penetrated in key markets METIS Brain Metastasis ENGOT-ov50/ INNOVATE-3 ‘Ovarian Cancer @ =1,000 addressable cases d
Slide 21: Multiple late-stage, randomized pivotal trials set to read out
novecure’ multiple late-stage, randomized pivotal trials set to read out in near-term MET PRIMARY ENDPOINT ENROLLMENT COMPLETE ENROLLMENT COMPLETE LUNAR Q ENGOT-ov50/ PANOVA-3 METIS Lung Cancer IN NOVATE-3 Pancreatic Cancer Brain Metastasis Ovarian Cancer + Evaluating TTFields with * Evaluating TTFi
Slide 22: Planned commercial pathway to treating NSCLC patients
novecure’ planned commercial pathway to treating NSCLC patients 5 2023 C 2024 2025 L COMMERCIAL LAUNCH * Activate physician and REGULATORY PATHWAY : : patient education CLINICAL DATA . lates pre-PMA discussions programs r ; with FDA * Treat on-protocol patients nnounce topline results * Submit PMA &
Slide 23: Deliver product innovation
novecure’ deliver product Innovation patientfo rward © 2023 Novocure GmbH 23
Slide 24: Product roadmap to prioritize dose and efficacy
product roadmap to prioritize dose and efficacy field generator arrays software applications next gen device new arrays MAXPOINT™ in development treating patients through planning software limited market release in development patient © 2023Novocure GmbH 24
Slide 25: Optimized dose delivered can lead to increased efficacy
novecure’ optimized dose delivered can lead to increased efficacy TUMOR TREATING FIELDS DOSE DELIVERED TIME ON xX FIELD INTENSITY xX CONDUCTIVITY om THERAPY TO TUMOR OF TISSUE —_ patientforward © 2023 Novocure GmbH 25 inalysis of Data from the Phase 5 EF-14 Randomized Trial. Int J Radiat Oncol Biol
Slide 26: New lighter, thinner arrays deliver greater intensity
novecure’ new lighter, thinner arrays deliver greater intensity EXISTING ARRAYS NEW ARRAYS AP channel, 1,364 mAmps AP channel, 1,685 mAmps In the first patient use, new arrays exhibited a improvement in field intensity in tumor region versus existing arrays patientforward © 2023 Novocure GmbH 26 Acr
Slide 27: Novocure: we strive to extend survival
novocure’ _— SET we strive to extend survival < ee in some of the most aggressive forms of ca GLOBAL OFFICES TEAM MEMBERS innovation focus da © 2023NovecureGmby 27
Slide 28: Appendix
novocure’ appendix patientforward*
Slide 29: Therapy is frequency-tuned to target dividing cancer cells
novecure’ therapy is frequency-tuned to target dividing cancer cells a TUMOR TREATING FIELDS 150 kHz 200 kHz Normal ntestine Intestin | | 50kHz 100 kHz 150 kHz 200 kHz 10 kHz 250 kHz Low Frequencies Intermediate High Frequencies DNA Damage cardiac defibrillator Frequencies radiofrequency ablation io
Slide 30: Ongoing trial designs
novecure’ ongoing trial designs patientfo rward © 2023Novocure GmbH 30
Slide 31: LUNAR study in non-small cell lung cancer
novecure’ LUNAR study in non-small cell lung cancer three post- progression follow-up visits TTFields + immune checkpoint LUNAR PIVOTAL, OPEN-LABEL, RANDOMIZED STUDY DESIGN? inhibitor/docetaxel progression on screening and or after platinu = baseline —— based therapy evaluation immune checkpoint fig
Slide 32: To be presented at a future medical congress
A TO BE PRESENTED AT A FUTURE MEDICAL CONGRESS ‘Trial design can be found on www clinicaltrials gov. INCTO2973789}. 0S, overall survival.
Slide 33: Ongoing INNOVATE-3 study in ovarian cancer
novecure’ ongoing INNOVATE-3 study in ovarian cancer INNOVATE-3 PIVOTAL, OPEN-LABEL, RANDOMIZED STUDY DESIGN* & TTFields + weekly [i CT/MRI scan q8w _ survival 7 s paclitaxel until progressi follow-up assis vals s weekly paclitaxel CT/MRI scan q8w [i survival S YP until progression follow-up Q ENGOT
Slide 34: Ongoing METIS study in brain metastases
novecure’ ongoing METIS study in brain metastases METIS PIVOTAL, OPEN-LABEL, RANDOMIZED STUDY DESIGN? yy ‘prosression 4 radiosurger Fields rogression screening a a7 “a sey Pele baseline evaluati . STUDY DESIGN 270 patients with 12 month minimum follow-up Primary endpoint: time to intracranial progre
Slide 35: Ongoing PANOVA-3 study in pancreatic cancer
ongoing PANOVA-3 study in pancreatic PANOVA-3 PIVOTAL, OPEN-LABEL, RANDOMIZED STUDY DESIGN* TTFields + nab-paclitaxel + gemcitabine CT q8w until progression post-PD follow up visit screening and baseline evaluation nab-paclitaxel + gemcitabine CT q8w until progression post-PD follow up visit randomi
Slide 36: Ongoing TRIDENT study in newly diagnosed GBM
novecure’ ongoing TRIDENT study in newly diagnosed GBM TRIDENT PIVOTAL, OPEN-LABEL, RANDOMIZED STUDY DESIGN* TTFields + RT TTFields + MRI q8w until + TMZ maintenance TMZ progression survival follow-up screening and baseline evaluation TTFields + MRI q8w until survival Ba spb, maintenance TMZ progres
Slide 37: Ongoing KEYNOTE B36 study in non-small cell lung cancer
novecure’ ongoing KEYNOTE B36 study in non-small cell lung cancer KEYNOTE B36 PILOT STUDY DESIGN! screening and TTFields (150 kHz) CT/MRI scan q9w until post-progression survival baseline evaluation JJ + pembrolizumab progression or 24 mo follow-up follow-up @ KEYNOTE B36 Lung Cancer STUDY DESIGN *
Slide 38: KEYNOTE D58 builds upon promising data from pilot 2-THE-TOP study
novecure’ KEYNOTE D58 builds upon promising data from pilot 2- THE-TOP study N=26 patients Median PFS : ° N=26 patients Median OS oa 2-THE-TOP | 12.1 mos. 2 2-THE-TOP | 25.2 mos. < 9 EF-14 matched-control 7.9 mos. 2 Ll EF-14 matched-control 15.9 mos s = 2 (HR = 0.46; p=0.033) $ I (HR = 0.38; p=0.020
Slide 39: Optune Lua and Optune indications for use and important safety information
novecure’ Optune Lua™ and Optune® indications for use and important safety information INDICATIONS » Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of
Slide 40: Optune Lua and Optune warnings and precautions
novecure’ Optune Lua™ and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event